<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38012892</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Use of inactivated poliovirus vaccine for poliovirus outbreak response.</ArticleTitle><Pagination><StartPage>e328</StartPage><EndPage>e342</EndPage><MedlinePgn>e328-e342</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(23)00505-4</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(23)00505-4</ELocationID><Abstract><AbstractText>With continued wild poliovirus transmission in Afghanistan and Pakistan and circulating vaccine-derived poliovirus in certain countries, there exists an ongoing risk of importation of polioviruses into other countries, including those that have been polio-free for decades. Diversifying the poliovirus outbreak response toolkit is essential to account for different public health and epidemiological contexts. In this Personal View, we discuss data on intestinal and pharyngeal mucosal immunity induced by inactivated poliovirus vaccine (IPV), previous programmatic experience of poliovirus outbreak response with IPV, and outbreak response guidelines in countries that exclusively use IPV. With recent reports of poliovirus detection in polio-free countries such as the USA and the UK, it is important to assess the interplay of virus transmission dynamics, vaccine impact on preventing paralysis and virus spread, and regulatory complexities of using oral poliovirus vaccine (OPV) and IPV options for outbreak response. As the global eradication programme navigates through cessation of routine OPV use with replacement by IPV and stockpiling of novel OPVs, clarity on the impact of IPV use will be important for informed decision making by global, regional, and national policy makers.</AbstractText><CopyrightInformation>Copyright Â© 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bandyopadhyay</LastName><ForeName>Ananda S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Bill &amp; Melinda Gates Foundation, Seattle, WA, USA. Electronic address: ananda.bandyopadhyay@gatesfoundation.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez Cavestany</LastName><ForeName>Rocio</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Polio Eradication Department, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blake</LastName><ForeName>Isobel M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macklin</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Polio Eradication Department, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassly</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nery</LastName><ForeName>Ana Leticia Melquiades Dos Santos</ForeName><Initials>ALMDS</Initials><AffiliationInfo><Affiliation>Bill &amp; Melinda Gates Foundation, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mach</LastName><ForeName>Ondrej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Polio Eradication Department, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Infect Dis. 2024 Feb;24(2):e83. doi: 10.1016/S1473-3099(23)00760-0</RefSource><PMID Version="1">38070529</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="Y">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="Y">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests We declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>27</Day><Hour>9</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>28</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38012892</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00505-4</ArticleId><ArticleId IdType="pii">S1473-3099(23)00505-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle>